InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-32.1%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Murphy Matthew B., Conseiller Juridique Général. Director active across 1 company, notably Nautilus Biotechnology, Inc.. In total, 4 filings have been logged. Split: 3 buys · 0 sell. Total volume traded: €50k. Activity tracked since 13 August 2021. The latest transaction was disclosed on 4 September 2025 (Acquisition). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Murphy Matthew B.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
20,000 shares@ US$0.642913.5% of flowCommon StockSEC:0001865778-25-000003:0
Canonical exit: 3 Dec 2025 (T+90)
2,500 shares@ US$2.856.7% of flowCommon StockSEC:0001808805-22-000093:0
Canonical exit: 10 Nov 2022 (T+90)
10,000 shares@ US$3.2838.7% of flowCommon StockSEC:0001808805-22-000056:0
5,000 shares@ US$7.561339.4% of flowCommon StockSEC:0001808805-21-000010:0
Canonical exit: 11 Nov 2021 (T+90)
4 of 4 declarations
About Murphy Matthew B.
Matthew B. Murphy is the General Counsel at Nautilus Biotechnology, Inc. In this role, he is responsible for the company's legal affairs and compliance. His expertise in business law is essential for advising management on legal and regulatory matters. He plays a key role in managing legal risks and protecting the company's interests.
